Clinical trials: Epilepsy, Motor Partial
Epilepsy, Motor Partial, Psychogenic Seizures
Detecting PNES With Single-channel sEMG
This is a prospective, comparative, multicenter study of subjects being admitted for standard of care therapy in Epilepsy Monitoring Units in the Veteran's Affair (VA) Medical Centers.
- Trial name
- NCT03313362
- Testing
- SPEAC System, video EEG
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Brain Sentinel
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Temporal Lobe Epilepsy
Exercise for Brain Regeneration in Epilepsy
Nearly 100 million Americans are affected by neurological disorders with an overall cost above $765 billion for the more prevalent conditions.
- Trial name
- NCT05179083
- Testing
- High-Impact Aerobic Exercise, Low-Impact Aerobic Exercise
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Epilepsia Partialis Continua, Kojewnikov's Epilepsy
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
- Conditions
- Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
- Trial name
- NCT02134366
- Testing
- Clobazam, Clonazepam, Lorazepam
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The Cooper Health System
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Biomarkers in Neurodegenerative Diseases
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD)
- Trial name
- NCT04055532
- Testing
- Neuraceq
- Where
- United States
- Sponsor
- University of Minnesota
Epilepsies, Partial
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
SP942 is a non-interventional post-authorization safety study (PASS) to evaluate the long-term safety and tolerability of Vimpat® (Lacosamide, LCM) as add-on treatment in patients with Epilepsy 16 years and older with…
- Trial name
- PASS (NCT00771927)
- Testing
- Lacosamide
- Where
- 62 sites in France, Germany and 3 more
- Volunteers
- 1,005 people
- Sponsor
- UCB Pharma
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
The purpose of this study is to obtain long-term safety and tolerability information on carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00744731
- Testing
- carisbamate
- Volunteers
- 403 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00740623
- Testing
- Carisbamate
- Volunteers
- 547 people
- Sponsor
- SK Life Science, Inc.
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Epilepsy, Drug Resistant
Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor…
- Trial name
- STEM (NCT06248333)
- Testing
- STN-DBS ON, STN-DBS OFF
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xuanwu Hospital, Beijing